Liver cancer drug combo put to the test – but trial stops early
Disease control
Terminated
This phase 3 trial compared a combination of two drugs (regorafenib and pembrolizumab) with standard locoregional therapies (TACE or TARE) as a first treatment for intermediate-stage liver cancer that has spread beyond certain limits. The study aimed to enroll about 496 people bu…
Phase: PHASE3 • Sponsor: Translational Research in Oncology • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC